Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation. However, the efficacy of these agents like erlotinib in patients without the mutation is not known. METHODS: This systematic review inc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jazieh, Abdul-Rahman, Al Sudairy, Reem, Abu-Shraie, Nada, Al Suwairi, Wafaa, Ferwana, Mazen, Murad, M. Hassan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Medknow Publications & Media Pvt Ltd 2013
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3821279/
https://ncbi.nlm.nih.gov/pubmed/24250733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1817-1737.118503
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak